Lanterne Dx Completes Merger with Flagship Biosciences, Expanding Biomarker and Digital Pathology Capabilities
Boulder, CO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Lanterne Dx, LLC, a discovery and clinical phase CRO offering histopathology and biomarker validation services to pharmaceutical and biotech customers, today announced it has completed its merger with Flagship Biosciences, Inc., a computational biology, data science, and d…
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Dash Social and Marquee Brands to Explore Brand Intelligence as the Next Competitive Advantage in AI at ADWEEK House During Advertising Week New York
- DRIVE TO THE NEXT VIBE: OMODA & JAECOO Responds to Global Young People's Expectations for Car Life with a Grand Event
- TopLine Credit Union Foundation Awards $47,500 in Scholarships
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →